Morgan Stanley’s Day 3 healthcare-conference takeaways emphasize pipeline, regulatory and commercial catalysts across six biotechnology companies

Overview

Morgan Stanley’s final-day conference note reviews management updates from six covered biotechnology companies. The discussions focused on portfolio growth beyond legacy products, upcoming clinical readouts, regulatory interactions, launch readiness and the commercial scale of several pipeline opportunities.

Core views

Incyte presented a long-term strategy to establish durable growth beyond Jakafi’s loss of exclusivity. Management said the ex-Jakafi core is annualizing at roughly $2 billion and aims to reach roughly $3–4 billion by 2030; a more de-risked late-stage pipeline could then support roughly 15–20% revenue CAGR during 2030–35. Five assets—povorcitinib, ’989, KRAS G12D, TGFβR2xPD-1 and latarcibart—are expected to drive about 80% of the recovery. In MPNs, Jakafi XR coverage is expected to reach 70–80% by year-end 2026, supporting patient conversion ahead of Jakafi LOE. In oncology, management described the KRAS G12D program as competitive and expects ESMO data in pancreatic and colorectal cancer. Dermatology launch preparation for povorcitinib includes coverage of more than 10,000 HS specialists, while Vega’s latarcibart adds a Phase 3 von Willebrand disease asset; management estimates roughly 30,000 patients could qualify for prophylaxis versus only about 2,000 treated today. Regenxbio reiterated confidence that RGX-202 could follow an accelerated approval path in Duchenne muscular dystrophy. Management emphasized its microdystrophin construct, AAV8 vector, proactive immune suppression and greater than 80% full-capsid purity. The company cited robust expression, particularly in older boys, liver-injury rates below one-tenth of those observed with Elevidys, and a statistically significant relationship between expression and NSAA change. A year-end pre-BLA meeting is expected to include safety data from 63 patients and biomarker data from 30 patients. The company sees an addressable U.S. ambulatory DMD population of roughly 5,000 patients and says it can produce 2,500 doses annually. Separately, Phase 3 wet AMD data for subretinal RGX-314 are expected in 4Q26; management believes a greater than 50% reduction in treatment burden would be clinically meaningful and highlighted data suggesting reductions of 70% or more. RGX-121 remains on clinical hold following asymptomatic spine MRI findings in five participants, with full evaluation expected to take six to nine months. AgomAb recently started the Phase 2b NOV-ERA study of ontunisertib in fibrostenotic Crohn’s disease, with FDA alignment on Week-24 endoscopic passability as the primary endpoint. In Phase 2a STENOVA, the 200mg twice-daily dose produced up to roughly 32% improvement in stricture passability at Week 12 versus roughly 7% for placebo. The company argues that local ALK5 inhibition could address fibrosis as well as inflammation, including potentially earlier in luminal Crohn’s disease. Management highlighted the inclusion of a 400mg twice-daily dose as evidence of the program’s favorable safety profile to date. Full open-label-extension data are expected later this year, with safety the main focus. AGMB-447, an inhaled lung-restricted ALK5 inhibitor, showed greater than 50% pSMAD3 reduction in BAL cells and is planned to enter a Phase 2 IPF study later this year using Week-24 FVC change as the primary endpoint. Attovia described ATTO-1310 as a potential treatment for the sizable chronic-itch market, estimating an approximately $11 billion U.S. peak-sales opportunity. The company believes ligand targeting of IL-31 could provide deeper and faster efficacy than receptor-targeting approaches, and cited Phase 1b signals after a single dose in chronic-pruritus and high-itch atopic-dermatitis patients. Serum free-IL-31 data supported the potential for quarterly dosing. Full 16-week Phase 1b data are due in 4Q26, although efficacy interpretation will be constrained by the single-dose design, small sample and rescue medication after Week 4. Phase 2 studies in chronic pruritus of unknown origin and high-itch mild-to-moderate atopic dermatitis are expected in 1H27, alongside early development of the broader ATTOBODY multispecific platform. Compass Pathways remains on track to complete the rolling COMP360 NDA submission in Q4, with a draft label and REMS framework already under FDA review. Management sees a potential 1H27 launch in treatment-resistant depression if the process proceeds as expected. It emphasized rapid onset within 24 hours, roughly 40% clinically meaningful response after two doses in COMP005/006, and evidence from COMP005 Part C that repeat dosing may extend benefit through one year. The anticipated initial regimen is two 25mg doses at least three weeks apart, followed by redosing at physician discretion, potentially totaling roughly two to four doses annually versus more frequent Spravato maintenance. Existing infrastructure includes roughly 8,500 treatment sites, adding about 500 per quarter. PTSD is the next potential expansion opportunity, with roughly 13 million U.S. patients and an ongoing late-stage study using an eight-week CAPS-5 primary endpoint. Arcutis reported continued Zoryve momentum, with foam representing more than 50% of franchise sales. Management reiterated $2.5–3.0 billion peak-sales potential from approved indications, while the branded non-steroidal topical category has grown from roughly 2% of the market at launch to nearly 10%; Zoryve is approaching roughly 50% of that segment. Expanded dermatology and primary-care/pediatric sales forces are intended to add growth through 2027. Access includes more than 80% commercial coverage, roughly 50% of Medicaid lives with single-step-or-better access and roughly one-third of Medicare lives covered. A February 2027 PDUFA for Zoryve in 3–24-month-old atopic dermatitis could add about one million patients to the addressable market. Topline proof-of-concept data and go/no-go decisions in vitiligo and hidradenitis suppurativa are expected in Q4, while ARQ-234 has entered multiple-ascending-dose testing.

Analysis framework

The report synthesizes management presentations and discussions from Morgan Stanley’s healthcare conference. It evaluates each company through the clinical profile of its lead programs, regulatory pathway and timing, addressable patient population, competitive positioning, manufacturing or launch readiness, and potential commercial expansion.

Methodology notes

• Industry AnalysisSupply-demand framework

  Patient-population and treatment-access analysis

  The report uses eligible patient populations, current treatment penetration, dosing burden and site infrastructure to frame potential demand and commercialization opportunities.

• Event-Driven and Behavioral FinanceEvent-driven analysis

  Clinical, regulatory and launch catalysts

  The analysis centers on upcoming data readouts, FDA meetings, NDA and BLA milestones, PDUFA dates, trial starts and commercialization events that could affect each company’s development path.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Incyte (INCY)

  Covered company; post-Jakafi growth transition

  Strengths

  Diversified late-stage pipeline, growing dermatology franchise and potential vWD opportunity from Vega.

  Weaknesses

  The growth framework requires replacement of revenue following Jakafi LOE.

  Comparison

  Povorcitinib is expected to have an approximately one-year head start versus Rinvoq in HS.

  Risks

  Pipeline and regulatory outcomes remain necessary to achieve the long-term growth framework.

• Regenxbio (RGNX)

  Covered company; gene-therapy regulatory and clinical catalyst

  Strengths

  Differentiated RGX-202 profile, potential manufacturing capacity and multiple retinal-disease opportunities.

  Weaknesses

  RGX-121 is subject to a clinical hold.

  Comparison

  Management cited substantially lower liver-injury rates than Elevidys and compares RGX-314 against Lucentis/Eylea treatment burden.

  Risks

  Accelerated approval, Phase 3 data and the RGX-121 safety review remain unresolved.

• AgomAb Therapeutics (AGMB)

  Covered company; anti-fibrotic development platform

  Strengths

  FDA-aligned Phase 2b design and local ALK5 inhibition intended to address fibrosis and inflammation.

  Weaknesses

  FSCD has limited development precedent.

  Comparison

  Existing Crohn’s therapies primarily target inflammation rather than fibrosis.

  Risks

  Clinical efficacy, safety and registrational-trial design remain to be established.

• Attovia Therapeutics (ATTO)

  Covered company; chronic-pruritus and multispecific biologics platform

  Strengths

  Potential differentiated IL-31 ligand targeting and a modular ATTOBODY platform.

  Weaknesses

  Current clinical evidence is early stage and based on limited single-dose data.

  Comparison

  Management contrasts ATTO-1310 with IL-31 receptor-targeting Nemluvio.

  Risks

  The 4Q26 readout has design limitations, including small sample size and rescue medication use.

• Compass Pathways (CMPS)

  Covered company; treatment-resistant depression launch candidate

  Strengths

  Rolling NDA progress, rapid-onset and durability data, and existing psychiatric-treatment infrastructure.

  Weaknesses

  Launch timing depends on FDA review, REMS and state rescheduling.

  Comparison

  COMP360 may require roughly two to four annual doses versus more frequent Spravato maintenance.

  Risks

  Regulatory review and commercialization assumptions remain key dependencies.

• Arcutis Biotherapeutics (ARQT)

  Covered company; dermatology commercial expansion

  Strengths

  Strong Zoryve momentum, expanding access and several pipeline extension opportunities.

  Weaknesses

  Growth is partly dependent on sales-force productivity and additional indications.

  Comparison

  Zoryve is approaching roughly 50% share of the branded non-steroidal topical segment.

  Risks

  Upcoming Q4 pipeline decisions and the February 2027 pediatric AD PDUFA are important milestones.

Key data

• Incyte ex-Jakafi revenue objective~$3–4B by 2030Management said the ex-Jakafi core is annualizing at approximately $2B today.
• Incyte potential revenue growth~15–20% CAGRManagement’s 2030–35 framework, contingent on a more de-risked late-stage pipeline.
• RGX-202 pre-BLA dataset63 safety patients; 30 biomarker patientsExpected to be available for the planned year-end FDA pre-BLA meeting.
• RGX-314 wet AMD data timing4Q26Topline Phase 3 data are expected for subretinal RGX-314.
• Ontunisertib Phase 2a passability result~32% vs ~7%Week-12 stricture-passability benefit for 200mg BID versus placebo in STENOVA.
• ATTO-1310 U.S. peak-sales opportunity~$11BAttovia’s estimate for chronic pruritus.
• COMP360 response rate~40%Clinically meaningful response after two doses in COMP005/006.
• Zoryve peak-sales outlook$2.5–3.0BManagement’s estimate from currently approved indications.

Impact & implications

The report portrays the group’s potential upside as dependent on execution against near- and medium-term clinical, regulatory and launch milestones. Across the companies, differentiated mechanisms, favorable emerging clinical profiles, broader addressable populations and improving commercial infrastructure are the principal drivers identified by management and Morgan Stanley.

Risks

• Incyte’s long-term recovery depends on clinical, regulatory and commercial success of its post-Jakafi portfolio.
• RGX-121 remains on clinical hold while Regenxbio evaluates spine MRI findings.
• Attovia noted that ATTO-1310 Phase 1b efficacy interpretation is limited by a single-dose design, small sample size and rescue medication use after Week 4.
• Compass’s anticipated launch timeline depends on completion of regulatory review and related implementation requirements.
• Arcutis’s pipeline expansion plans depend on upcoming proof-of-concept data and regulatory outcomes.

What to watch

• Incyte’s ESMO and ASH presentations, Q4 dermatology data and Jakafi XR coverage progress.
• Regenxbio’s year-end RGX-202 pre-BLA meeting, 4Q26 RGX-314 data and RGX-121 safety review.
• AgomAb’s STENOVA open-label-extension data later this year and Phase 2 progress for ontunisertib and AGMB-447.
• Attovia’s 4Q26 ATTO-1310 Phase 1b results and planned 1H27 Phase 2 and Phase 1 trial starts.
• Compass’s Q4 NDA completion, FDA review process and potential 1H27 COMP360 launch.
• Arcutis’s Q4 vitiligo and HS decisions, Zoryve sales-force contribution and February 2027 pediatric AD PDUFA.